Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention

Background: High-sensitivity C-reactive protein (hsCRP) predicts outcomes after percutaneous coronary intervention (PCI). Objective: We studied the prevalence and prognostic impact of hsCRP elevation according to age in men and women undergoing PCI. Methods: We included patients undergoing PCI at our center from 2010 until 2017, excluding those with myocardial infarction (MI) on presentation, neoplastic disease and hsCRP >10 mg/L at baseline. Elevated hsCRP was defined as >3 mg/L. The outcome of interest was major adverse cardiac events (MACE) consisting of all-cause death, MI and target vessel revascularization. The association between hsCRP elevation and outcomes was assessed using adjusted Cox models. Results: 10,432 men and 4,345 women were included. Elevation of hsCRP was present in 25.7% of men and 37.0% of women (p <.01). In men, prevalence of hsCRP elevation was stable across age strata (p_trend =.42). In women, hsCRP elevation was most prevalent in patients <50 years (44.6%) and decreased stepwise with increasing age (p_trend <.001). After stratifying the population into age quartiles (Q1: <59 years, Q2: 59–66 years, Q3: 67–74 years, Q4: ≥75 years), hsCRP elevation was associated with increased risk of MACE across all age groups in men (HR [95% CI] Q1: 1.49 [1.12–1.98]; Q2: 1.51 [1.21–2.06]; Q3: 1.76 [1.27–2.51]; Q4: 1.43[1.03–1.97]). In women, hsCRP elevation was associated with increased risk of MACE only among older patients (HR [95% CI] Q1: 1.08 [0.64–0.82]; Q2: 1.52 [0.93–2.46]; Q3: 1.65 [1.08–2.50]; Q4: 1.52 [1.02–1.28]). Conclusion: Among patients undergoing PCI, prevalence and prognostic value of hsCRP elevation were age-dependent exclusively in women.